PALB2 and breast cancer: UK health economic analysis undertaken in 2018 suggest universal testing of BRCA1, BRCA2 and PALB2 genes for BC patients to be economically impactful within NICE willingness to pay thresholds of £30,000/QALY up to a per-patient cost of £1,626 (payer perspective) and £1,868 (societal perspective) [22].